Scott Nicholas Gettinger MD

Associate Professor Of Medicine (Medical Oncology)

Specialties & Subspecialties

Cancer Center, Yale: Thoracic Oncology Program

Internal Medicine: Medical Oncology

Education & Training

  • B.S., Trinity College (CT) (1991)
  • M.D., State University of New York At Brooklyn College (1999)
  • Resident, Beth Israel Medical Center, NY , Internal Medicine  (1999 - 2002)
  • Fellow, Beth Israel Medical Center, NY , Medical Oncology and Hematology  (2002 - 2005)

Patient Care

Accepts New Patients? Yes | Patient Type: Adult | Accepts referrals from patients


Clinical Interests

Lung cancer; mesothelioma; thymoma; head and neck cancer; thyroid cancer; mediastinal and chest wall tumors


Cancers Treated

Chest Wall Tumors, Lung, Mediastinal Tumors, Mesothelioma, Thymomas


Board Certifications

  • Hematology, Board Eligible
  • Medical Oncology, Board Certified (2005)

Clinical Trials

Conditions Study Title
Breast Cancer (ER, PR, and HER2 negative), Colorectal Cancer, Endometrial Cancer, Gastric Adenocarcinoma, Glioblastoma Multiforme, Head/ Neck Squamous Cell Carcinoma, Melanoma, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Prostate Cancer, Brain and Nervous System, Breast - Female, Breast - Male, Colon, Lip, Oral Cavity and Pharynx, Lung, Melanoma, skin, Other Female Genital, Ovary, Prostate, Rectum, and Stomach A Phase I/IIa, First Time in human, open-label dose-escalation study of GSK2636771 in subjects with advanced solid tumors with PTEN deficiency
Lung A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects With Advanced Non-Small Cell Lung Cancer
Bladder, Breast - Female, Lung, Pancreas, and Stomach A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors
Lung and Melanoma, skin A Phase 2 Study of MK-3475 in patients with metastatic melanoma and non-small cell lung cancer with untreated brain metastases
Lung A Phase 2b, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects with Unresectable Pleural or Peritoneal Malignant Mesothelioma

More Clinical Trials...

Edit Profile